Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer (Review)

Sacco,Keith; Muhammad,Aun; Saleem,Waqar; Alshaker,Heba; Monzon,Leonardo; Islam,Mohammad Rafiqul; Pchejetski,Dmitri

doi:10.3892/ol.2016.4745

Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer (Review)

Authors:
- Keith Sacco
- Aun Muhammad
- Waqar Saleem
- Heba Alshaker
- Leonardo Monzon
- Mohammad Rafiqul Islam
- Dmitri Pchejetski
View Affiliations

Affiliations: Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London W12 0NN, UK, Mont Vernon Hospital, Middlesex HA6 2RN, UK, Faculty of Pharmacy and Medical Sciences, Petra University, Amman 00962, Jordan, Department of Imaging, St Mary's Hospital, London W2 1NY, UK, Guys and St Thomas Hospital, London SE1 9RT, UK, School of Medicine, University of East Anglia, Norwich NR4 7TJ, UK
Published online on: June 16, 2016 https://doi.org/10.3892/ol.2016.4745
Pages: 779-782

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Leptomeningeal metastasis (LM) is an uncommon presentation of relapse in breast cancer, which is associated with poor clinical outcomes and poor prognosis. Notably, LM most commonly occurs in breast cancer. The aim of the present review was to investigate the occurrence of LM as the primary presentation of relapse following remission in breast cancer patients and to determine whether specific histological subtypes are predisposed to meningeal metastases. In addition, the present review evaluated whether patients presenting with LM as the primary site of relapse exhibit differences in survival when compared with patients exhibiting metastasis to other sites. Cross‑sectional studies have demonstrated that LM is commonly associated with other sites of distant metastasis including lung, liver and bone metastases. The histological breast cancer subtype most commonly associated with LM was invasive lobular carcinoma, while triple‑negative breast cancer patients appear to be predisposed to the development of LM when considering the overall prevalence of histological breast cancer subtypes. At present, data regarding LM as the primary site of relapse are limited due to its rarity as the first site of metastasis in breast cancer. Case‑controlled studies are required to investigate the incidence of LM as the primary site of recurrence in breast cancer patients as this would enable treatment standardization and identification of prognostic factors for improved survival.

View Figures

View References

1	Pace A and Fabi A: Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol. 60:194–200. 2006. View Article : Google Scholar : PubMed/NCBI
2	Amer MH, Al-Sarraf M, Baker LH and Vaitkevicius VK: Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer. 42:660–668. 1978. View Article : Google Scholar : PubMed/NCBI
3	Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, Glatstein EJ, Wiernik PH, Lichter AS and Bunn PA Jr: Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the national cancer institute experience. Medicine (Baltimore). 61:45–53. 1982. View Article : Google Scholar : PubMed/NCBI
4	Chamberlain MC: Neoplastic meningitis. J Clin Oncol. 23:3605–3613. 2005. View Article : Google Scholar : PubMed/NCBI
5	Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L and Diéras V: Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 21:2183–2187. 2010. View Article : Google Scholar : PubMed/NCBI
6	Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, Penas-Prado M and Groves MD: Breast cancer and leptomeningeal disease (LMD): Hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 114:229–235. 2013. View Article : Google Scholar : PubMed/NCBI
7	Niwińska A, Rudnicka H and Murawska M: Breast cancer leptomeningeal metastasis: Propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol. 30:4082013. View Article : Google Scholar : PubMed/NCBI
8	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yap HY, Yap BS, Tashima CK, DiStefano A and Blumenschein GR: Meningeal carcinomatosis in breast cancer. Cancer. 42:283–286. 1978. View Article : Google Scholar : PubMed/NCBI
10	Lara-Medina F, Crismatt A, Villarreal-Garza C, Alvarado-Miranda A, Flores-Hernández L, González-Pinedo M, Gamboa-Vignolle C, Ruiz-González JD and Arrieta O: Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J. 18:233–241. 2012. View Article : Google Scholar : PubMed/NCBI
11	Meattini I, Livi L, Saieva C, Franceschini D, Marrazzo L, Greto D, Scotti V, Scoccianti S, Paiar F, Bordi L, et al: Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: A single center experience. J Chemother. 24:279–284. 2012. View Article : Google Scholar : PubMed/NCBI
12	Glantz MJ, Van Horn A, Fisher R and Chamberlain MC: Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 116:1947–1952. 2010. View Article : Google Scholar : PubMed/NCBI
13	Torrejón D, Oliveira M, Cortes J, Sanchez-Olle G, Gómez P, Bellet M, Saura C, Peg V, Rovira A and Di Cosimo S: Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast. 22:19–23. 2013. View Article : Google Scholar : PubMed/NCBI
14	de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF and Gimenes DL: Meningeal carcinomatosis in breast cancer: Prognostic factors and outcome. J Neurooncol. 104:565–572. 2011. View Article : Google Scholar : PubMed/NCBI
15	Le Rhun E, Zairi F, Baranzelli MC, Faivre-Pierret M, Devos P and Bonneterre J: Primary breast cancer phenotype associated with propensity for leptomeningeal metastases. EJC Supplements. 8:1992010. View Article : Google Scholar
16	Niwińska A, Murawska M and Pogoda K: Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer. 116:4238–4247. 2010. View Article : Google Scholar : PubMed/NCBI
17	Jayson GC and Howell A: Carcinomatous meningitis in solid tumours. Ann Oncol. 7:773–786. 1996. View Article : Google Scholar : PubMed/NCBI
18	Lamovec J and Zidar A: Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 115:507–510. 1991.PubMed/NCBI
19	Chamberlain MC and Johnston SK: Neoplastic meningitis: Survival as a function of cerebrospinal fluid cytology. Cancer. 115:1941–1946. 2009. View Article : Google Scholar : PubMed/NCBI
20	Karnofsky DA and Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of Chemotherapeutic Agents. MacLeod CM: Columbia University Press; New York, NY: pp. pp191–205. 1949
21	Boogerd W, Hart AA, van der Sande JJ and Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer. 67:1685–1695. 1991. View Article : Google Scholar : PubMed/NCBI
22	Chamberlain MC and Kormanik PA: Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 54:1364–1368. 1997. View Article : Google Scholar : PubMed/NCBI
23	Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, Akerley W, Marin L and Choy H: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer. 75:2919–2931. 1995. View Article : Google Scholar : PubMed/NCBI
24	Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, Porsok S and Mardiak J: Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast. 20:478–480. 2011. View Article : Google Scholar : PubMed/NCBI